← Leaderboards
Jeannine S McCune
Fred Hutchinson Cancer Research Center
$7,454,702
Attributed
$8,054,705
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2008–21$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$10,267,728 · 8
By mechanism
R01$5,161,810 · 3
U54$2,213,023 · 1
U01$1,819,552 · 1
R21$660,400 · 1
P20$238,893 · 1
R03$174,050 · 1
Top collaborators
- Donald E Mager2 shared
- Mary F Paine2 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- George McDonald$1,319,623
Others in their field
Top investigators on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Sharon A Nachman · Johns Hopkins University$194,646,762
- Carol Nesel · Westat$147,274,423
- Barbara Driver · Westat, Inc.$103,746,400
- Ronald T Mitsuyasu · University Of California Los Angeles$99,239,507
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
Research focus
Drug KineticsPharmaceutical PreparationsBaseIn VitroPlasmaDosePharmacokinetic ModelSamplingRegimenAllogenicToxic EffectScheduleAreaResponseMalignant NeoplasmsEquilibriumExposure ToDatabasesResourcesCohortHematopoietic Cell TransplantationProdrugsCellsConditioning
Grant awards (25)
Optimizing GVHD Prevention with Systems Pharmacology Models$600,003
U01 · FY2021 · CA · contact PI
Project 2$79,631
P20 · FY2021 · CA · contact PI
Optimizing GVHD Prevention with Systems Pharmacology Models$600,003
U01 · FY2020 · CA · contact PI
Project 2$79,631
P20 · FY2020 · CA · contact PI
Optimizing GVHD Prevention with Systems Pharmacology Models$619,546
U01 · FY2019 · CA · contact PI
Cyclophosphamide Pharmacokinetics and Pharmacometabolomics$326,910
R01 · FY2019 · GM · contact PI
Project 2$79,631
P20 · FY2019 · CA · contact PI
Optimizing Busulfan: Efficacy Toxicity and Pharmacometabolomics$515,038
R01 · FY2018 · CA · contact PI
Cyclophosphamide Pharmacokinetics and Pharmacometabolomics$345,161
R01 · FY2018 · GM · contact PI
Optimizing Busulfan: Efficacy Toxicity and Pharmacometabolomics$515,038
R01 · FY2017 · CA · contact PI
Natural Product-Drug Interaction Research: The Roadmap to Best Practices$284,531
U54 · FY2017 · AT · contact PI
Natural Product-Drug Interaction Research: The Roadmap to Best Practices$1,928,492
U54 · FY2016 · AT · contact PI
Optimizing Busulfan: Efficacy Toxicity and Pharmacometabolomics$286,571
R01 · FY2016 · CA · contact PI
Optimizing Busulfan: Efficacy, Toxicity, and Pharmacometabolomics$180,734
R01 · FY2016 · CA · contact PI
Optimizing Busulfan: Efficacy, Toxicity, and Pharmacometabolomics$474,714
R01 · FY2015 · CA · contact PI
Optimizing Busulfan: Efficacy, Toxicity, and Pharmacometabolomics$494,325
R01 · FY2014 · CA · contact PI
Pharmacogenetics in children with high-risk neuroblastoma$75,598
R03 · FY2014 · CA · contact PI
Pharmacogenetics in children with high-risk neuroblastoma$98,452
R03 · FY2013 · CA · contact PI
Pharmacogenetics of Cyclophosphamide ADRs in$316,620
R21 · FY2012 · CA · contact PI
Population Pharmacokinetics/Pharmacodynamics in Nonablative Stem Cell Recipients$427,179
R01 · FY2011 · HL · contact PI
Pharmacogenetics of Cyclophosphamide ADRs in$343,780
R21 · FY2011 · CA · contact PI
Population Pharmacokinetics/Pharmacodynamics in Nonablative Stem Cell Recipients$427,307
R01 · FY2010 · HL · contact PI
Population Pharmacokinetics/Pharmacodynamics in Nonablative Stem Cell Recipients$427,950
R01 · FY2009 · HL · contact PI
Population Pharmacokinetics/Pharmacodynamics in Nonablative Stem Cell Recipients$293,934
R01 · FY2009 · HL · contact PI
Population Pharmacokinetics/Pharmacodynamics in Nonablative Stem Cell Recipients$446,949
R01 · FY2008 · HL · contact PI